jeudi 31 octobre 2019

Onco Actu du 31 octobre 2019


1. BIOLOGIE



Tumors Turn Gut ‘Brain Cells’ Into Tumor Growth Promoters [North Carolina State University]











Senescent cells feed on their neighbours [Nature]










2.6 ETIOLOGIE - ENVIRONNEMENT



Bayer says U.S. farmers unfazed by glyphosate litigation [Reuters]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Real-Time Digital Surveillance of Vaping-Induced Pulmonary Disease [NEJM]











Vaping and lung disease in the US: PHE’s advice [Public Health England]










3.3 PRÉVENTION - VACCINS



Merck siphons off Gardasil CDC supplies again as global sales surge [Fierce Pharma]










4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Implantable cancer traps could provide earlier diagnosis, help monitor treatment [University of Michigan]











4.10 DÉP., DIAG. & PRONO. - POUMON



Mitochondria’s activity in lung tumors could predict response to treatment [UCLA]











4.12 BIOPSIES LIQUIDES



Liquid Biopsy Shows Promise in New Brain Cancer Study [Genome Web]











3D-Printed Device Finds ‘Needle in a Haystack’ Cancer Cells by Removing the Hay [Georgia Tech]











Blood Test Can Predict Prognosis in Deadly Brain Cancer [Penn Medicine]










4.5 DÉP., DIAG. & PRONO. - COLORECTAL



Exact Sciences Presents New Stool-Based Colorectal Cancer Screening Performance Data, Initiates Prospective Screening Study [Exact Sciences]











5. TRAITEMENTS



The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature [Amgen]











Two new drugs finally hit ‘undruggable’ cancer target, providing hope for treatments [Science]











5.10 TRAITEMENTS - ESSAIS



Phase I trials: not all are made equal [Nature Reviews Clinical Oncology]










New England Journal of Medicine Publishes Results from Astellas’ Phase 3 ADMIRAL Trial of XOSPATA® (gilteritinib) in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia [Astellas]











Phase I/II Study Results with Lorlatinib in ROS1-positive Advanced NSCLC [ESMO]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



New research suggests proton radiation therapy can benefit patients with challenging liver tumors [ASTRO]











5.2 PHARMA



GlaxoSmithKline's RIPK1 inhibitor dead on arrival [Fierce Biotech]











A RIP1 contender fails to make the cut at GSK after a fast fizzle in pancreatic cancer [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



FDA task force offers suggestions to reduce drug shortages [Fierce Pharma]











6.10 POLITIQUES



Europe’s incoming research chief must act to head off budget cuts [Nature]











6.6 PUBLICATIONS



Nonsense Lives On in the Citations [In The Pipeline]











6.7.2 APPLIS



NIH Grant Funds Fitness App for Geriatric Oncology [university of Rochester]